Shots:
- Novartis has reported topline P-III (VAYHIT2) trial data assessing ianalumab (3 or 9mg/kg, QM, IV) + eltrombopag vs PBO + eltrombopag in pts with primary immune thrombocytopenia (ITP) who failed 1L corticosteroid treatment
- Trial met its 1EP with prolonged time to treatment failure & showed increased sustained platelet count improvement at 6mos. (2EP); data will be presented at a future meeting & included in regulatory filings in 2027 with results from the ongoing P-III (VAYHIT1) trial for primary ITP
- Ianalumab is being evaluated in P-III trials for 1L ITP as well as 2L & later-line warm autoimmune hemolytic anemia, with results from both B cell-driven autoimmune disease studies expected in 2026
Ref: Novartis | Image: Novartis | Press Release
Related News:- Novartis Reports Topline P-III (NEPTUNUS-1 & 2) Trials Finding on Ianalumab to Treat Active Sjögren’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
